Blood-based Lung Cancer Screening Test Earns FDA Breakthrough Device Designation

NAQC Newsroom: Tobacco Control

Blood-based Lung Cancer Screening Test Earns FDA Breakthrough Device Designation

Thursday, August 20, 2026
Posted by: Natalia Gromov

CancerNetwork – The FDA has granted Breakthrough Device designation to a blood-based lung cancer screening test, SimpleScreen Lung. Presented at the 2026 American Association for Cancer Research Annual Meeting, data showcased the potential of this test for detecting lung cancer through a simple blood sample.
Learn more.

« Back to Index

Latest News more

21 hours agoNAQC Community Highlights - September 2026 Issue

9/1/2026NAQC Advisory Council: Nominations for New Members by September 30

8/31/2026Webinar on September 1 - State and Health Systems Partnership Models

Calendar more

The upcoming calendar is currently empty.

Click here to view past events and photos »

NORTH AMERICAN QUITLINE CONSORTIUM

The North American Quitline Consortium (NAQC) is an international, non-profit membership organization based in Phoenix, Arizona. NAQC seeks to promote evidence-based quitline services across diverse communities in North America.

About

History
Mission, Goals & Vision
Our People
Membership
Quitline Map

CONTACT

SubscRibe TO MONTHLY CONNECTIONS

Connections is our monthly e-newsletter designed to keep NAQC members and partners connected to timely information about tobacco control, research, and upcoming events in the quitline community.

Sign Me Up!

- 3219 E. Camelback Road, #416, Phoenix, AZ 85018
- Ph: 800.398.5489
- Fax: 800.398.5489
- email:naqc@naquitline.org

	Edit This Favorite
Name:
Category:
Share:	Yes No, Keep Private

Edit This Favorite

Blood-based Lung Cancer Screening Test Earns FDA Breakthrough Device Designation